Across TCGA pan-cancer cohorts, SUMO2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SUMO2 data layer compared with 23 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SUMO2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SUMO2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

LUAD, HNSC, and PDAC are the cancer types where SUMO2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	II,III,IV	1.000	0.706	.012	7	view →
HNSC	DFS	Median	II,III,IV	0.741	0.573	.039	1	view →
PDAC	DFS	Quartile	II,III,IV	0.766	0.661	.040	1	view →
LSCC	OS	Tertile	All	1.000	0.961	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: SUMO2 tumor-vs-normal RNA expression · all SUMO2 data types